Cancer Immunotherapy

[ASAP] Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy

[ASAP] Design, Synthesis, and Pharmacological Evaluation of Quinazoline and Quinoline Derivatives as Potent ENPP1 Inhibitors for Cancer Immunotherapy

Anti-PD-1 treatment for MSI-H/MMRD tumors. A journey from genomics to transformative patient breakthroughs

André and colleagues present the final report on the impactful results of the Keynote-177 trial after 5 years of OS follow-up.1 The roots of this breakthrough that has led to the incorporation of anti-PD-1 agents into the treatment algorithm of patients with MSI-H/MMRD tumors stretch back to 1993, when Manuel Perucho and Bert Vogelstein respective… Continue reading Anti-PD-1 treatment for MSI-H/MMRD tumors. A journey from genomics to transformative patient breakthroughs

Scientists identify a new cancer immunotherapy target: Dysfunctional B cells

Scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood — known as the tertiary lymphoid structure — where they become frustratingly dysfunctional when in close contact with tumors.

Making Biliary Tract Cancer Treatment More Precise

Tumors arising in the gallbladder, bile ducts, and the small intestine are collectively referred to as biliary tract cancers. These cancers are rare—affecting approximately 12,350 individuals in 2024—but they are typically diagnosed at advanced stages when surgery, which can improve prognosis, is no longer an option. Angela Lamarca, MD, PhD Systemic therapies, therefore, are the… Continue reading Making Biliary Tract Cancer Treatment More Precise

Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2 -Positive Breast Cancer

This 10-year follow-up analysis of the ShortHER randomized clinical trial evaluates the association of tumor-infiltrating lymphocytes with distant disease-free and overall survival among patients with ERBB2 (formerly HER2)–positive early breast cancer.

How cancer cells trick the immune system by altering mitochondria

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment. However, cancer cells have developed immune evasion strategies, leading to poor treatment responses. Now, researchers have identified the transfer of mitochondria with mutated DNA from cancer cells to immune cells as a key mechanism of immune evasion and resistance to… Continue reading How cancer cells trick the immune system by altering mitochondria

Comparison of survival outcomes for patients with Lynch vs non‐Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy

Abstract Background Alterations in mismatch repair (MMR) genes like MLH1, MSH2, MSH6, and PMS2 can lead to microsatellite instability–high (MSI-H) tumors. These mutations can be inherited, as in Lynch syndrome (LS), or occur de novo. Although immune checkpoint inhibitors (ICI) improves survival in MSI-H colorectal cancer (CRC) compared to chemotherapy, data comparing outcomes for patients with… Continue reading Comparison of survival outcomes for patients with Lynch vs non‐Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy

New mechanism of immune evasion discovered in cancer cells

The immune system plays a key role in detecting and destroying cancer cells. Cancer immunotherapy works by programming immune cells to recognize and eliminate cancer cells. However, many cancers can escape immune surveillance through various mechanisms, resulting in resistance to treatment. This highlights the need to better understand the molecular processes that enable immune evasion. … Continue reading New mechanism of immune evasion discovered in cancer cells